The Opioid Epidemic in the United States

Emergency Medicine Clinics of North America

Volumn 34, Issue 2, 2016, Pages e1-e23

  Wilkerson, Richard Gentry ^a   Kim, Hong K ^a   Windsor, Thomas Andrew ^a   Mareiniss, Darren P ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Heroin; Legal liability; Opioid epidemic; Opioids; Overdose; Prescription drugs

Indexed keywords

NALOXONE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; CHRONIC CONSTIPATION; CLINICAL PRACTICE; COST OF ILLNESS; CRIMINAL JUSTICE; DELIRIUM; DRUG INTOXICATION; DRUG MISUSE; DRUG OVERDOSE; DRUG SAFETY; EMERGENCY CARE; EMERGENCY HEALTH SERVICE; HEALTH HAZARD; HEART ARRHYTHMIA; HEROIN DEPENDENCE; HOME CARE; HUMAN; INTRAVENOUS DRUG ABUSE; MEDICOLEGAL ASPECT; OPIATE ADDICTION; PAIN; PATIENT EDUCATION; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RESPIRATORY DISTRESS; REVIEW; RISK FACTOR; SEIZURE; SHORT BOWEL SYNDROME; TREND STUDY; UNITED STATES; WITHDRAWAL SYNDROME; OPIOID-RELATED DISORDERS;

ANALGESICS, OPIOID; HUMANS; OPIOID-RELATED DISORDERS; PAIN; PRESCRIPTION DRUG MISUSE; RISK FACTORS; UNITED STATES;

EID: 84958093317     PISSN: 07338627     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.emc.2015.11.002     Document Type: Review

References (147)

1. Rosenblum A., Marsch L.A., Joseph H., et al. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol 2008, 16(5):405.
2. Davis A. Paracelsus: a quincentennial assessment. J R Soc Med 1993, 86(11):653-656.
3. Hayes A.N., Gilbert S.G. Historical milestones and discoveries that shaped the toxicology sciences. Molecular, clinical and environmental toxicology. Vol 1 Molecular toxicology 2009, 1-35. Birkhäuser Verlag AG, Basel (Switzerland). A. Luch (Ed.).
4. Sneader W. The discovery of heroin. Lancet 1998, 352(9141):1697-1699.
5. Kramer J.C. Heroin in the treatment of morphine addiction. J Psychoactive Drugs 1977, 9(3):193-197.
6. Amoli H.A., Golozar A., Keshavarzi S., et al. Morphine analgesia in patients with acute appendicitis: a randomised double-blind clinical trial. Emerg Med J 2008, 25(9):586-589.
7. Attard A.R., Corlett M.J., Kidner N.J., et al. Safety of early pain relief for acute abdominal pain. BMJ 1992, 305(6853):554-556.
8. Gallagher E.J., Esses D., Lee C., et al. Randomized clinical trial of morphine in acute abdominal pain. Ann Emerg Med 2006, 48(2):150-160.e1-e4.
9. Thomas S.H., Silen W., Cheema F., et al. Effects of morphine analgesia on diagnostic accuracy in emergency department patients with abdominal pain: a prospective, randomized trial. J Am Coll Surg 2003, 196(1):18-31.
10. Kockler N.J. The principle of double effect and proportionate reason. Virtual Mentor 2007, 9(5):369-374.
11. Fins J.J. Acts of omission and commission in pain management: the ethics of naloxone use. J Pain Symptom Manage 1999, 17(2):120-124.
12. Gureje O., Von Korff M., Simon G.E., et al. Persistent pain and well-being: a World Health Organization study in primary care. JAMA 1998, 280(2):147-151.
13. Porter J., Jick H. Addiction rare in patients treated with narcotics. N Engl J Med 1980, 302(2):123.
14. Portenoy R.K., Foley K.M. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 1986, 25(2):171-186.
15. Melzack R. The tragedy of needless pain. Sci Am 1990, 262(2):27-33.
16. Goldman B. Use and abuse of opioid analgesics in chronic pain. Can Fam Physician 1993, 39:571-576.
17. Wilson J.E., Pendleton J.M. Oligoanalgesia in the emergency department. Am J Emerg Med 1989, 7(6):620-623.
18. Campbell J.N. APS 1995 Presidential address. J Pain 1996, 5(1):85-88.
19. Ducharme J. Emergency pain management: a Canadian Association of Emergency Physicians (CAEP) consensus document. J Emerg Med 1994, 12(6):855-866.
20. Afilalo M., Cantees K., Ducharme J. Current pain-control practices and research. Ann Emerg Med 1996, 27(4):404-407.
21. Mularski R.A., White-Chu F., Overbay D., et al. Measuring pain as the 5th vital sign does not improve quality of pain management. J Gen Intern Med 2006, 21(6):607-612.
22. Phillips D.M. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations. JAMA 2000, 284(4):428-429.
23. Harden R.N. Chronic pain and opiates: a call for moderation. Arch Phys Med Rehabil 2008, 89(3):S72-S76.
24. Cantrill S.V., Brown M.D., Carlisle R.J., et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Emerg Med 2012, 60(4):499-525.
25. Center for Behavioral Health Statistics and Quality Results from the 2011 National survey on drug Use and health: summary of national findings (HHS publication No. SMA 12-4713, NSDUH series H-44) 2012, Substance Abuse and Mental Health Services Administration, Rockville (MD).
26. National Vital Statistics System Multiple cause of death file 2012, Centers for Disease Control and Prevention, Atlanta (GA), Available at: www.cdc.gov/nchs/data/dvs/Record_Layout_2012.pdf.
27. Centers for Disease Control and Prevention WONDER [database] 2013, US Department of Health and Human Services; Centers for Disease Control and Prevention, Atlanta (GA).
28. Jones C.M., Mack K.A., Paulozzi L.J. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013, 309(7):657-659.
29. Drossman D., Szigethy E. The narcotic bowel syndrome: a recent update. Am J Gastroenterol 2014, 2(1):22-30.
30. Rolita L., Spegman A., Tang X., et al. Greater number of narcotic analgesic prescriptions for osteoarthritis is associated with falls and fractures in elderly adults. J Am Geriatr Soc 2013, 61(3):335-340.
31. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The DAWN Report: Highlights of the 2011 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. Rockville (MD). Available at: Accessed December 10, 2015. http://www.samhsa.gov/data/sites/default/files/DAWN127/DAWN127/sr127-DAWN-highlights.pdf.
32. Paulozzi L., Jones C., Mack K., et al. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid analgesics-United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011, 60(43):1487-1492.
33. Coalition Against Insurance Fraud. Prescription for Peril: How Insurance Fraud Finances Theft and Abuse of Addictive Prescription Drugs. Available at: Accessed December 10, 2015. http://www.insurancefraud.org/downloads/drugDiversion.pdf.
34. Hansen R.N., Oster G., Edelsberg J., et al. Economic costs of nonmedical use of prescription opioids. Clin J Pain 2011, 27(3):194-202.
35. Behavioral Health Coordinating Committee Prescription Drug Abuse Subcommittee, U.S. Department of Health and Human Services. Addressing Prescription Drug Abuse in the United States Current Activities and Future Opportunities. 2013. Available at: Accessed December 10, 2015. http://www.cdc.gov/drugoverdose/pdf/hhs_prescription_drug_abuse_report_09.2013.pdf.
36. McCabe S.E., West B.T., Boyd C.J. Leftover prescription opioids and nonmedical use among high school seniors: a multi-cohort national study. J Adolesc Health 2013, 52(4):480-485.
37. Jones C.M. Frequency of prescription pain reliever nonmedical use: 2002-2003 and 2009-2010. Arch Intern Med 2012, 172(16):1265-1267.
38. Platts-Mills T.F., Hunold K.M., Bortsov A.V., et al. More educated emergency department patients are less likely to receive opioids for acute pain. Pain 2012, 153(5):967-973.
39. Centers for Disease Control and Prevention (CDC) Overdose deaths involving prescription opioids among Medicaid enrollees - Washington, 2004-2007. MMWR Morb Mortal Wkly Rep 2009, 58(42):1171-1175.
40. Hall A.J., Logan J.E., Toblin R.L., et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008, 300(22):2613-2620.
41. Becker W.C., Sullivan L.E., Tetrault J.M., et al. Non-medical use, abuse and dependence on prescription opioids among US adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend 2008, 94(1):38-47.
42. Mowry J.B., Spyker D.A., Cantilena L.R., et al. 2013 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 31st Annual Report. Clin Toxicol 2014, 52(10):1032-1283.
43. Centers for Disease Control and Prevention (CDC) Vital signs: risk for overdose from methadone used for pain relief - United States, 1999-2010. MMWR Morb Mortal Wkly Rep 2012, 61(26):493-497.
44. Warner M., Paulozzi L., Nolte K., et al. State variation in certifying manner of death and drugs involved in drug intoxication deaths. Acad Forensic Pathol 2013, 3(2):231-237.
45. McDonald D.C., Carlson K., Izrael D. Geographic variation in opioid prescribing in the US. J Pain 2012, 13(10):988-996.
46. Dart R.C., Surratt H.L., Cicero T.J., et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015, 372(3):241-248.
47. Rudd R.A., Paulozzi L.J., Bauer M.J., et al. Increases in heroin overdose deaths-28 states, 2010 to 2012. MMWR Morb Mortal Wkly Rep 2014, 63(39):849-854.
48. Reifler L.M., Droz D., Bailey J.E., et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse?. Pain Med 2012, 13(3):434-442.
49. Cicero T.J., Ellis M.S., Surratt H.L. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012, 367(2):187-189.
50. Maxwell J.C. The pain reliever and heroin epidemic in the United States: shifting winds in the perfect storm. J Addict Dis 2015, 34(2-3):127-140.
51. Hedegaard H., Chen L., Warner M. Drug-poisoning deaths involving heroin: United States, 2000-2013 2015, CDC; National Center for Health Statistics, Hyattsville (MD).
52. Substance Abuse and Mental Health Services Administration (SAMHSA) Results from the 2013 National Survey on Drug Use and Health: summary of national findings, NSDUH Series H-48, HHS Publication No. (SMA) 14-4863 2014, Substance Abuse and Mental Health Services Administration, Rockville (MD), Available at:, Accessed December 10, 2015. http://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf.
53. Martins S.S., Santaella-Tenorio J., Marshall B.D., et al. Racial/ethnic differences in trends in heroin use and heroin-related risk behaviors among nonmedical prescription opioid users. Drug Alcohol Depend 2015, 151:278-283.
54. Cicero T.J., Ellis M.S., Surratt H.L., et al. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 2014, 71(7):821-826.
55. Jones C.M., Logan J., Gladden R., et al. Vital signs: demographic and substance use trends among heroin users: United States, 2002-2013. MMWR Morb Mortal Wkly Rep 2015, 64(26):719-725.
56. Muhuri PK, Gfroerer JC, Davies MC. Associations of nonmedical pain reliever use and initiation of heroin use in the United States. The CBHSQ data review. 2013.
57. Drug Enforcement Administration National drug threat assessment summary 2014 2015, US Department of Justice; Drug Enforcement Administration, Washington, DC, Pub. no. DEA-DCT-DIR-002-15. Available at:, Accessed December 10, 2015. http://www.dea.gov/resource-center/dir-ndta-unclass.pdf.
58. Drug Enforcement Administration National heroin threat assessment summary 2015, US Department of Justice; Drug Enforcement Administration, Washington, DC, Pub. no. DEA-DCT-DIR-039-15.
59. Foldes F.F., Lunn J.N., Moore J., et al. N-Allynoroxymorphone: a new potent narcotic antagonist. Am J Med Sci 1963, 245(1):57-64.
60. Martin W.R. Drugs five years later: naloxone. Ann Intern Med 1976, 85(6):765-768.
61. Sgherza A.L., Axen K., Fain R., et al. Effect of naloxone on perceived exertion and exercise capacity during maximal cycle ergometry. J Appl Physiol (1985) 2002, 93(6):2023-2028.
62. Foldes F.F. The human pharmacology and clinical use of narcotic antagonists. Med Clin North Am 1964, 48:421-443.
63. Mannelli M., Maggi M., De Feo M.L., et al. Effects of naloxone on catecholamine plasma levels in adult men. A dose-response study. Acta Endocrinol (Copenh) 1984, 106(3):357-361.
64. Kim H.K., Nelson L.S. Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf 2015, 14(7):1137-1146.
65. Cuss F.M., Colaco C.B., Baron J.H. Cardiac arrest after reversal of effects of opiates with naloxone. Br Med J (Clin Res Ed) 1984, 288(6414):363-364.
66. Andree R.A. Sudden death following naloxone administration. Anesth Analg 1980, 59(10):782-784.
67. Manfredi P.L., Ribeiro S., Chandler S.W., et al. Inappropriate use of naloxone in cancer patients with pain. J Pain Symptom Manage 1996, 11(2):131-134.
68. Kim H.K., Nelson L.S. Reversal of opioid-induced ventilatory depression using low-dose naloxone (0.04 mg): a case series. J Med Toxicol 2015, [Epub ahead of print].
69. Goldfrank's toxicologic emergencies 2015, McGraw-Hill Education, New York. 10th edition. R.S. Hoffman, M.A. Howland, N.A. Lewin (Eds.).
70. Connors N.J., Nelson L.S. Wide variation in naloxone dosing recommendations for acute opioid toxicity. J Med Toxicol 2014, 10:76-77.
71. Doyon S. Opioids. Tintinalli's emergency medicine: a comprehensive study guide 2011, 1230-1234. McGraw-Hill, New York. 7th edition. J.E. Tintinalli, J.S. Stapczynski (Eds.).
72. Bardsley C.H. Opioids. Rosen's emergency medicine-concepts and clinical practice 2014, 2052-2056. Saunders/Elsevier, Philadelphia. 8th edition. J.A. Marx, R.S. Hockberger, R.M. Walls (Eds.).
73. Foldes F.F., Schapira M., Torda T.A., et al. Studies on the Specificity of Narcotic Antagonists. Anesthesiology 1965, 26:320-328.
74. Sadove M.S., Balagot R.C., Hatano S., et al. Study of a narcotic antagonist-n-allyl-noroxymorphone. JAMA 1963, 183(8):666-668.
75. Mills C.A., Flacke J.W., Miller J.D., et al. Cardiovascular effects of fentanyl reversal by naloxone at varying arterial carbon dioxide tensions in dogs. Anesth Analgesia 1988, 67(8):730-736.
76. Mills C.A., Flacke J.W., Flacke W.E., et al. Narcotic reversal in hypercapnic dogs: comparison of naloxone and nalbuphine. Can J Anaesth 1990, 37(2):238-244.
77. Goldfrank L., Weisman R.S., Errick J.K., et al. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med 1986, 15(5):566-570.
78. Clarke S.F., Dargan P.I., Jones A.L. Naloxone in opioid poisoning: walking the tightrope. Emerg Med J 2005, 22(9):612-616.
79. Boyer E.W. Management of opioid analgesic overdose. N Engl J Med 2012, 367(2):146-155.
80. Watson W.A., Steele M.T., Muelleman R.L., et al. Opioid toxicity recurrence after an initial response to naloxone. Clin Toxicol 1998, 36(1-2):11-17.
81. Hendra T.J., Gerrish S.P., Forrest A.R. Fatal methadone overdose. BMJ 1996, 313(7055):481-482.
82. Sarton E., Teppema L., Dahan A. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine. Adv Exp Biol 2008, 605:486-491.
83. van Dorp E., Yassen A., Sarton E., et al. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology 2006, 105(1):51-57.
84. Bigg D. Data on take home naloxone are unclear but not condemnatory. BMJ 2002, 324(7338):678.
85. Doe-Simkins M., Walley A.Y., Epstein A., et al. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health 2009, 99(5):788-791.
86. Enteen L., Bauer J., McLean R., et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health 2010, 87(6):931-941.
87. Walley A.Y., Xuan Z., Hackman H.H., et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013, 346:f174.
88. Samuels E. Emergency department naloxone distribution: a Rhode Island department of health, recovery community, and emergency department partnership to reduce opioid overdose deaths. R I Med J (2013) 2014, 97(10):38-39.
89. Community management of opioid overdose 2014, World Health Organization, Geneva (Switzerland), Available at:, Accessed December 10, 2015. http://www.who.int/substance:abuse/publications/management_opioid_overdose/en/.
90. Wheeler E., Jones T.S., Gilbert M.K., et al. Opioid overdose prevention programs providing naloxone to laypersons-United States, 2014. Morb Mortal Wkly Rep 2015, 64(23):631-635.
91. Ashworth A.J., Kidd A. Take home naloxone for opiate addicts. Apparent advantages may be balanced by hidden harms. BMJ 2001, 323(7318):935.
92. Strang J., Powis B., Best D., et al. Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. Addiction 1999, 94(2):199-204.
93. Aberer W., Maurer M., Reshef A., et al. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema. Allergy 2014, 69(3):305-314.
94. Wampler D.A., Molina D.K., McManus J., et al. No deaths associated with patient refusal of transport after naloxone-reversed opioid overdose. Prehosp Emerg Care 2011, 15(3):320-324.
95. Winston I., McDonald R., Tas B., et al. Heroin overdose resuscitation with naloxone: patient uses own prescribed supply to save the life of a peer. BMJ Case Rep 2015, 2015. 10.1136/bcr-2015-210391.
96. Strang J., Bird S.M., Parmar M.K. Take-home emergency naloxone to prevent heroin overdose deaths after prison release: rationale and practicalities for the N-ALIVE randomized trial. J Urban Health 2013, 90(5):983-996.
97. NPR: Price soars for key weapon against heroin overdoses. Available at: Accessed September 21, 2015. http://www.npr.org/sections/health-shots/2015/09/10/439219409/naloxone-price-soars-key-weapon-against-heroin-overdoses.
98. Almendrala A. Huffington Post: Clinton Foundation to help make anti-overdose drug much more affordable. Available at: Accessed September 21, 2015. http://www.huffingtonpost.com/2015/01/26/evzio-naloxone-clinton-foundation_n_6550554.html.
99. Sporer K.A. Acute heroin overdose. Ann Intern Med 1999, 130(7):584-590.
100. Powis B., Strang J., Griffiths P., et al. Self-reported overdose among injecting drug users in London: extent and nature of the problem. Addiction 1999, 94(4):471-478.
101. Williams A.V., Marsden J., Strang J. Training family members to manage heroin overdose and administer naloxone: randomized trial of effects on knowledge and attitudes. Addiction 2014, 109(2):250-259.
102. Seal K.H., Thawley R., Gee L., et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health 2005, 82(2):303-311.
103. Gabay M. The Federal Controlled Substances Act: Schedules and Pharmacy Registration. Hosp Pharm 2013, 48(6):473.
104. The Network for Public Health Law. Legal intervention to reduce overdose mortality: Naloxone access and overdose Good Samaritan laws. 2015. Available at: Accessed September 2, 2015. https://www.networkforphl.org/_asset/qz5pvn/network-naloxone-10-4.pdf.
105. Burris S., Beletsky L., Castagna C.A., et al. Stopping an invisible epidemic: legal issues in the provision of naloxone to prevent opioid overdose. Drexel Law Review 2009, 1(2):273-339.
106. The Network for Public Health Law. Using law to support pharmacy naloxone distribution: Issue Brief. Available at: Accessed September 2, 2015. https://www.networkforphl.org/_asset/qdkn97/Pharmacy-Naloxone-Distributions.pdf.
107. Example of Collaborative Practice Agreement from Washington State. Available at: Accessed September 2, 2015. http://www.stopoverdose.org/docs/cdtasample.pdf.
108. Massachusetts Department of Public Health Opioid Overdose Education and Naloxone Distribution: MDPH Naloxone Pilot Project Core Competencies. Available at: Accessed September 2, 2015. http://www.mass.gov/eohhs/docs/dph/substance-abuse/core-competencies-for-naloxone-pilot-participants.pdf.
109. Doyon S., Aks S.E., Schaeffer S. Expanding access to naloxone in the United States. Clin Toxicol 2014, 52(10):989-992.
110. Tracy M., Piper T.M., Ompad D., et al. Circumstances of witnessed drug overdose in New York City: implications for intervention. Drug Alcohol Depend 2005, 79(2):181-190.
111. Banta-Green C.J., Beletsky L., Schoeppe J.A., et al. Police officers' and paramedics' experiences with overdose and their knowledge and opinions of Washington State's drug overdose-naloxone-Good Samaritan law. J Urban Health 2013, 90(6):1102-1111.
112. Wagner K.D., Valente T.W., Casanova M., et al. Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. Int J Drug Policy 2010, 21(3):186-193.
113. N.M. Stat. Ann. § 24-23-2 (2001).
114. Mass. Gen. Laws ch. 94c § 19 (d) (2012).
115. Lagu T., Anderson B.J., Stein M. Overdoses among friends: drug users are willing to administer naloxone to others. J Subst Abuse Treat 2006, 30(2):129-133.
116. Spears v. State, 929 So. 2d 477 (Ala. Civ. App. 2005).
117. People v. Besz, 802 N.E.2d 841 (Ill. App. Ct. 2003).
118. Pletcher M.J., Kertesz S.G., Kohn M.A., et al. Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. JAMA 2008, 299(1):70-78.
119. Mazer-Amirshahi M., Mullins P.M., Rasooly I., et al. Rising opioid prescribing in adult US emergency department visits: 2001-2010. Acad Emerg Med 2014, 21(3):236-243.
120. Volkow N.D., McLellan T.A., Cotto J.H., et al. Characteristics of opioid prescriptions in 2009. JAMA 2011, 305(13):1299-1301.
121. American Academy of Physical Medicine and Rehabilitation. Pain Management and opioid prescribing policies by state. 2014. Available at: Accessed August 30, 2015. http://www.aapmr.org/advocacy/outreach/AAPMR%20Documents/Pain-Management-and-Opioid-Prescribing-Policies-By-State.pdf.
122. Arkansas Department of Health. Arkansas emergency department opioid prescribing guidelines. Available at: Accessed August 30, 2015. http://www.aapmr.org/advocacy/outreach/AAPMR%20Documents/Pain-Management-and-Opioid-Prescribing-Policies-By-State.pdf.
123. California American College of Emergency Physicians. Safe pain medicine prescribing. Available at: Accessed August 31, 2015. http://californiaacep.org/wp-content/uploads/CAL-ACEP_ED-Handout_8-5x11_ENG_v8.pdf.
124. Connecticut State Medical Society. Connecticut emergency department opioid prescribing guidelines. 2015. Available at: Accessed August 31, 2015. http://documents.cthosp.org/9/Opioid%20Guidelines%20FINAL%201_20_2015.pdf.
125. Martins H.S., Silva R.V., Bugano D., et al. Should naloxone be prescribed in the ED management of patients with cardiac arrest? A case report and review of literature. Am J Emerg Med 2008, 26(1):113.e5-113.e8.
126. Hawaii American College of Emergency Physicians. Hawaii emergency department opioid guidelines. 2014. Available at: Accessed August 30, 2015. http://www.hawaiiacep.org/uploadedFiles/Hawaii/Best%20Practices.pdf.
127. Maine American College of Emergency Physicians. Emergency department opioid prescribing guidelines. 2014. Available at: Accessed August 30, 2015. http://www.maineacep.org/Resources/.
128. Opioid prescribing guidelines for Oklahoma workgroup. Oklahoma emergency department (ED) and urgent care clinic (UCC) opioid prescribing guidelines. 2015. Available at: Accessed August 30, 2015. http://www.ok.gov/health2/documents/UP_Oklahoma_ED-UCC_Guidelines.pdf.
129. Oregon College of Emergency Physicians. Oregon emergency department (ED) opioid prescribing guidelines. 2012. Available at: Accessed August 30, 2015. http://www.ocep.org/images/pdf/ed_opioid_abuse_guidelines.pdf.
130. Pennsylvania College of Emergency Physicians. Pennsylvania guidelines: Emergency department (ED) pain treatment guidelines. 2014. Available at: Accessed August 30, 2015. http://www.pamedsoc.org/DocumentVault/VaultPDFs/PatientcarePDFs/ER-opioid-guidelines-PDF.pdf.
131. Maryland American College of Emergency Physicians. Maryland emergency department and acute care facility guidelines for prescribing opioids. 2014. Available at: Accessed August 30, 2015. http://www.mdacep.org/MD%20ACEP%20Pamphlet%20FINAL_April%202014.pdf.
132. Cheng D, Majlesi N, Heller M, et al. Clinical practice statement: Emergency department opioid prescribing guidelines for the treatment of non-cancer related pain. 2013. Available at: Accessed August 31, 2015. http://www.aaem.org/UserFiles/file/Emergency-Department-Opoid-Prescribing-Guidelines.pdf.
133. Emergency Department Opioid Abuse Workgroup. Washington Emergency Department Opioid Prescribing Guidelines. 2011. Available at: Accessed December 15, 2012. http://washingtonacep.org/Postings/edopioidabuseguidelinesfinal.pdf.
134. New York City Department of Health and Mental Hygiene. New York City emergency department discharge opioid prescribing guidelines. 2013. Available at: Accessed August 31, 2015. http://www.nyc.gov/html/doh/downloads/pdf/basas/opioid-prescribing-guidelines.pdf.
135. Juurlink D.N., Dhalla I.A., Nelson L.S. Improving opioid prescribing: the New York City recommendations. JAMA 2013, 309(9):879-880.
136. National Association of State Controlled Substances Authorities. Prescription monitoring programs. 2014. Available at: Accessed August 29, 2015. http://www.nascsa.org/nascsaPMP/NationalPDMPmap1.26.14.pdf.
137. Missouri prescription drug monitoring program NOW coalition. Get the facts. 2015. Available at: Accessed August 29, 2015. http://mopdmpnow.com/get-the-facts/.
138. Haffajee R.L., Jena A.B., Weiner S.G. Mandatory use of prescription drug monitoring programs. JAMA 2015, 313(9):891-892.
139. Baehren D.F., Marco C.A., Droz D.E., et al. A statewide prescription monitoring program affects emergency department prescribing behaviors. Ann Emerg Med 2010, 56(1):19-23.e1-e3.
140. Griggs C.A., Weiner S.G., Feldman J.A. Prescription drug monitoring programs: examining limitations and future approaches. West J Emerg Med 2015, 16(1):67.
141. Haegerich T.M., Paulozzi L.J., Manns B.J., et al. What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend 2014, 145:34-47.
142. Brady J.E., Wunsch H., DiMaggio C., et al. Prescription drug monitoring and dispensing of prescription opioids. Public Health Rep 2014, 129(2):139-147.
143. Prescription Drug Monitoring Program Center of Excellence at Brandeis. COE Briefing. Mandating PDMP participation by medical providers: current status and experience in selected states. 2014. Available at: Accessed August 30, 2015. http://www.pdmpexcellence.org/sites/all/pdfs/COE%20briefing%20on%20mandates%20revised_a.pdf.
144. Del Portal D.A., Healy M.E., Satz W.A., et al. Impact of an opioid prescribing guideline in the acute care setting. J Emerg Med 2015, [Epub ahead of print].
145. Levy B., Paulozzi L., Mack K.A., et al. Trends in opioid analgesic-prescribing rates by specialty, US, 2007-2012. Am J Prev Med 2015, 49(3):409-413.
146. Conrardy M., Lank P., Cameron K.A., et al. Emergency department patient perspectives on the risk of addiction to prescription opioids. Pain Med 2015, [Epub ahead of print].
147. Smith R.J., Rhodes K., Paciotti B., et al. Patient perspectives of acute pain management in the era of the opioid epidemic. Ann Emerg Med 2015, 66(3):246-252.e1.